NextCure, Inc. (NXTC)
NASDAQ · Healthcare
NextCure, Inc. EBITDA 2020–2025
NextCure, Inc. annual/quarterly ebitda history and growth rate from 2020 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- NextCure, Inc. ebitda for the quarter ending March 31, 2026 was -9.8 M, a 10.45% decrease year-over-year.
- NextCure, Inc. ebitda for the twelve months ending March 31, 2026 was -54.3 M.
- NextCure, Inc. annual ebitda for 2025 was -55.4 M, a 7.01% increase from 2024.
- NextCure, Inc. annual ebitda for 2024 was -51.8 M, a 19.00% decrease from 2023.
- NextCure, Inc. annual ebitda for 2023 was -64.0 M, a 10.91% decrease from 2022.
- NextCure, Inc. annual ebitda for 2022 was -71.8 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
NextCure, Inc. EBITDA — FAQ
NextCure, Inc. (NXTC) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see NXTC's ebitda history?
The chart and table above show NextCure, Inc.'s ebitda by year and by quarter, including the growth rate.